PURPOSE: To retrospectively review data of a cohort of patients with biochemical progression after radical prostatectomy, treated according to a uniform institutional treatment policy, to evaluate toxicity and feasibility of high-dose salvage radiation therapy (80 Gy).
METHODS AND MATERIALS: Data on 60 patients with biochemical progression after radical prostatectomy between January 2009 and September 2011 were reviewed. The median value of prostate-specific antigen before radiation therapy was 0.9 ng/mL. All patients at time of diagnosis of biochemical recurrence underwent dynamic 18F-choline positron emission tomography/computed tomography (PET/CT), which revealed in all cases a local recurrence. High-dose salvage radiation therapy was delivered up to total dose of 80 Gy to 18F-choline PET/CT-positive area. Toxicity was recorded according to the Common Terminology Criteria for Adverse Events, version 3.0, scale.
RESULTS: Treatment was generally well tolerated: 54 patients (90%) completed salvage radiation therapy without any interruption. Gastrointestinal grade ≥2 acute toxicity was recorded in 6 patients (10%), whereas no patient experienced a grade ≥2 genitourinary toxicity. No grade 4 acute toxicity events were recorded. Only 1 patient (1.7%) experienced a grade 2 gastrointestinal late toxicity. With a mean follow-up of 31.2 months, 46 of 60 patients (76.6%) were free of recurrence. The 3-year biochemical progression-free survival rate was 72.5%.
CONCLUSIONS: At early follow-up, 18F-choline PET/CT-driven high-dose salvage radiation therapy seems to be feasible and well tolerated, with a low rate of toxicity.
Written by:
D'Angelillo RM, Sciuto R, Ramella S, Papalia R, Jereczek-Fossa BA, Trodella LE, Fiore M, Gallucci M, Maini CL, Trodella L. Are you the author?
Radiation Oncology, Campus Bio-Medico University, Rome, Italy; Department of Nuclear Medicine, Regina Elena National Cancer Institute, Rome, Italy; Department of Urology, Regina Elena National Cancer Institute, Rome, Italy; Department of Radiation Oncology, European Institute of Oncology, Milan, Italy; Department of Health Sciences, University of Milan, Milan, Italy.
Reference: Int J Radiat Oncol Biol Phys. 2014 Jul 29. pii: S0360-3016(14)00701-9.
doi: 10.1016/j.ijrobp.2014.05.050
PubMed Abstract
PMID: 25084612
UroToday.com Prostate Cancer Section
